The blocking of PD-1 and PD-L1 often have different immunological effects, while the blocking of PD-L1 not only activates T cells, but also elicits a non-T-cell (e.g., TAMs)-dependent anti-tumor response. The gene discussed is PDCD1; the disease is neoplasm.